Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It's on Twitter... ASCO Results

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 04, 2023 7:49pm

196 Views

Post# 35479562

RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO Results

Yes, I agree with you Noteable. The efficacy of pela on its own means we can be viewed as and valued as an agent that kills cancer, not just an immune stimulant.

That is highly significant.

I have not seen or looked up the IND 213 results to see if the pfs on that trial at the same time out from treatment is comparable. But if we can manage to get comparable OS results to IND 213, we will have done well.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing